PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11347331-10 2000 After methylprednisolone and cyclophosphamide application the suppressor/inducer CD8+ T-cells increased significantly in percentage (P < 0.05), while the values of B-lymphocytes decrease significantly (P < 0.05), in contrast to the results from the methylprednisolone-only treatment. Cyclophosphamide 29-45 CD8a molecule Homo sapiens 81-84 14698862-0 2004 Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis. Cyclophosphamide 0-16 CD8a molecule Homo sapiens 120-123 14698862-9 2004 We report here that in patients with secondary progressive MS, cyclophosphamide induces a marked increase in the percentage of CCR4(+) T cells that produce high levels of IL-4 and reverses the increase in the percentages of IFN-gamma-producing CCR5(+) and CXCR3(+) CD8(+) T cells. Cyclophosphamide 63-79 CD8a molecule Homo sapiens 265-268 14698862-10 2004 Furthermore, therapy with cyclophosphamide increases IL-4-producing CD4(+) T cells and reverses the increase in IFN-gamma-producing CD8(+) T cells. Cyclophosphamide 26-42 CD8a molecule Homo sapiens 132-135 8844499-10 1996 We observed a decrease in the percentage of CD3+CD8+ in patients treated with methylprednisolone/cyclophosphamide. Cyclophosphamide 97-113 CD8a molecule Homo sapiens 48-51 2145216-7 1990 Activation of these CD8+ T cells was indicated by the finding that they were rapidly converted from being cyclophosphamide (Cy) resistant to being highly Cy sensitive within 48 hr of giving Vb. Cyclophosphamide 106-122 CD8a molecule Homo sapiens 20-23 8231237-0 1993 Cyclophosphamide treatment of an SJL murine B-cell lymphoma increases the proportion of suppressive CD8+ over tumor-stimulatory CD4+ T-lymphocytes. Cyclophosphamide 0-16 CD8a molecule Homo sapiens 100-103 8231237-3 1993 Cyclophosphamide treatment of tumor-bearing mice (RCS/Cy) decreases in vitro tumor-stimulated CD4+ T-cell proliferation and, in turn, tumor growth, in part, through the suppressive action of CD8+ T-lymphocytes. Cyclophosphamide 0-16 CD8a molecule Homo sapiens 191-194 1766265-9 1991 This is the first report of regression of proven monoclonal CD8+ T gamma-cell expansion and the associated anemia following cyclophosphamide therapy. Cyclophosphamide 124-140 CD8a molecule Homo sapiens 60-63 7751644-6 1995 A single, low dose (20 mg/kg) of the DNA-targeted drug cyclophosphamide (Cy) caused a massive decrease in frequency for the responding CD8+ CTLp, though the mice survived infection with the HKx31 virus and there was no long-term exhaustion of the CTLp pool in the MLN, spleen, or lung. Cyclophosphamide 55-71 CD8a molecule Homo sapiens 135-138 7751644-6 1995 A single, low dose (20 mg/kg) of the DNA-targeted drug cyclophosphamide (Cy) caused a massive decrease in frequency for the responding CD8+ CTLp, though the mice survived infection with the HKx31 virus and there was no long-term exhaustion of the CTLp pool in the MLN, spleen, or lung. Cyclophosphamide 73-75 CD8a molecule Homo sapiens 135-138 1672870-3 1991 Cyclophosphamide/ACTH infusions significantly decreased the proportion of peripheral blood CD4+ T cells at 2, 6 and 12 months following treatment while there was a tendency for increased CD8 expression. Cyclophosphamide 0-16 CD8a molecule Homo sapiens 187-190 2145216-7 1990 Activation of these CD8+ T cells was indicated by the finding that they were rapidly converted from being cyclophosphamide (Cy) resistant to being highly Cy sensitive within 48 hr of giving Vb. Cyclophosphamide 124-126 CD8a molecule Homo sapiens 20-23 2145216-7 1990 Activation of these CD8+ T cells was indicated by the finding that they were rapidly converted from being cyclophosphamide (Cy) resistant to being highly Cy sensitive within 48 hr of giving Vb. Cyclophosphamide 154-156 CD8a molecule Homo sapiens 20-23 34224377-0 2021 Correction: Cyclophosphamide and Vinorelbine Activate Stem-Like CD8+ T Cells and Improve Anti-PD-1 Efficacy in Triple-Negative Breast Cancer. Cyclophosphamide 12-28 CD8a molecule Homo sapiens 64-67 33897897-5 2021 Meanwhile, chemical immunomodulatory drug cyclophosphamide (CP) was also encapsulated in the vesicle (CD64-NVs-aPD-L1-CP), to simultaneously restrain the regulatory T cells (Tregs) and invigorate Ki67+CD8+ T cells, then further enhance their anti-tumor ability. Cyclophosphamide 42-58 CD8a molecule Homo sapiens 201-204 2787959-0 1989 Marrow hypoplasia associated with a monoclonal CD8 large granular lymphocyte proliferation: reversal with cyclophosphamide and prednisone. Cyclophosphamide 106-122 CD8a molecule Homo sapiens 47-50 2960008-3 1987 It appears that Cyclophosphamide is able to correct the CD4/CD8 ratio imbalance observed in most MS patients and that this correction is generally associated with a beneficial effect on the disease. Cyclophosphamide 16-32 CD8a molecule Homo sapiens 60-63 33268528-0 2021 Cyclophosphamide and vinorelbine activate stem-like CD8+ T cells and improve anti-PD-1 efficacy in triple-negative breast cancer. Cyclophosphamide 0-16 CD8a molecule Homo sapiens 52-55 21908423-5 2011 The CCR4 antagonist was more efficient than cyclophosphamide to elicit anti-self CD8(+) T cells. Cyclophosphamide 44-60 CD8a molecule Homo sapiens 81-84 30063143-6 2018 Furthermore, when a low dose of cyclophosphamide (CP) was loaded into PD-1-expressing platelets to deplete regulatory T cells (Tregs), an increased frequency of reinvigorated CD8+ lymphocyte cells was observed within the postsurgery tumor microenvironment, directly preventing tumor relapse. Cyclophosphamide 32-48 CD8a molecule Homo sapiens 175-178 28132769-3 2017 Intravenous administration of cyclophosphamide (37.5 mg/kg body weight) resulted in immunosuppresion induction, as significant drops were observed in blood leukocytes and lymphocyte subset counts (CD2+, CD4+, CD8+, CD19+), lasting 3-10 days after its administration. Cyclophosphamide 30-46 CD8a molecule Homo sapiens 209-212 27980738-2 2016 Clinicians should be aware of this differential diagnosis because CD8+ T-cell lymphoma prognosis can be remarkably favorable upon oral treatment with cyclophosphamide. Cyclophosphamide 150-166 CD8a molecule Homo sapiens 66-69 31143518-6 2019 Moreover, a combination of the anti-ICOS mAb with cyclophosphamide reduced tumor growth, and that was associated with an improved CD8 to Treg ratio. Cyclophosphamide 50-66 CD8a molecule Homo sapiens 130-133 30262565-5 2019 When comparing the influence of anti-T-cell therapy, a delay in the reconstitution of the naive CD8+ T-cell repertoire was observed in patients who received in vivo T-cell depletion using antithymocyte globulin or post-transplantation cyclophosphamide in case of haploidentical transplantation. Cyclophosphamide 235-251 CD8a molecule Homo sapiens 96-99 28815584-3 2017 Fifty percent of CD8+ memory T lymphocytes in the spleen are eliminated by cyclophosphamide within 14 days, indicating that numbers of at least 50% of splenic CD8+ memory T lymphocytes are maintained by proliferation. Cyclophosphamide 75-91 CD8a molecule Homo sapiens 17-20 29114880-7 2017 47: 1900-1905) argue against this dogma, as they provide evidence that CD8 memory T cells in murine bone marrow are not proliferating, but largely quiescent, which protects them from elimination by the cytostatic drug Cyclophosphamide. Cyclophosphamide 218-234 CD8a molecule Homo sapiens 71-74 26041539-8 2015 Using Rag2(-/-) mice or depletion of recipient CD8(+) T cells after CPA treatment abrogated the augmentation of antitumor effects in CPA-treated reconstituted mice. Cyclophosphamide 133-136 CD8a molecule Homo sapiens 47-50 23507054-8 2013 We recommend especially to monitor neutrophiles, lymphocytes and if needed CD3-, CD4- and CD8-cell counts in patients receiving steroids and cyclophosphamide or other cytotoxic agents. Cyclophosphamide 141-157 CD8a molecule Homo sapiens 90-93 22539294-5 2012 Our data indicate that adoptive transfer of donor-derived T-cell receptor (TCR) alphabeta(+) CD3(+) CD4(-) CD8(-) NK1.1(-) (double negative, DN) Treg cells prior to C57BL/6 to BALB/c BM transplantation, in combination with cyclophosphamide, induced a stable-mixed chimerism and acceptance of C57BL/6 skin allografts but rejection of third-party C3H (H-2k) skin grafts. Cyclophosphamide 223-239 CD8a molecule Homo sapiens 107-110 22285846-0 2012 Cyclophosphamide inhibits the generation and function of CD8(+) regulatory T cells. Cyclophosphamide 0-16 CD8a molecule Homo sapiens 57-60 22285846-10 2012 These data demonstrate that CD8(+) Treg are inhibited through cytotoxic phenomena by CY, thus supporting the use of this drug at adequate concentrations and schedules of administration as a Treg inhibitor in combinatorial chemo- or immunotherapeutic anticancer protocols. Cyclophosphamide 85-87 CD8a molecule Homo sapiens 28-31 22720230-2 2012 Disruption of tumor microenvironment homeostasis by low-dose cyclophosphamide prior to interleukin-12 gene therapy led to CD8+ T cell-driven established tumor rejection. Cyclophosphamide 61-77 CD8a molecule Homo sapiens 122-125 17198082-0 2007 Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. Cyclophosphamide 24-40 CD8a molecule Homo sapiens 89-92 18410892-2 2008 We show that treatment of mice with cyclophosphamide (Cy) followed by CD8(+) T cell-depleted allogeneic donor lymphocyte infusion (Cy + CD8(-) DLI) induces regression of established tumors with minimal toxicity in models of both hematologic and solid cancers, even though the donor cells are eventually rejected by the host immune system. Cyclophosphamide 54-56 CD8a molecule Homo sapiens 136-139 20857100-7 2011 Analysis of peripheral blood samples from patients prior and during fludarabine/cyclophosphamide therapy revealed rapid and sustained reduction of tumour cells but also of CD4(+) and CD8(+) T cells. Cyclophosphamide 80-96 CD8a molecule Homo sapiens 183-186